Clinical trial
SURMOUNT-4: continuation and withdrawal are different questions
A randomized withdrawal design examined maintenance after an initial treatment period.
Read the study note ↗THE RESEARCH LIBRARY
Read the research.
Keep the context.
190 source-linked study notes. Explore the design, findings and limits behind the headline.
190 study notes Page 8 of 16
Clinical trial
SURMOUNT-OSA: sleep-disordered breathing as a trial endpoint
Two trials examined sleep-apnea measurements in adults with obesity.
Read the study note ↗Clinical trial
SYNERGY-NASH: interpreting phase 2 liver-biopsy outcomes
The dose-finding study reported MASH resolution but called for larger and longer trials.
Read the study note ↗Follow-up study
TAZPOWER at 168 weeks: what an open-label follow-up can add
The longer report followed the same trial program, rather than providing an independent randomized replication.
Read the study note ↗Clinical trial
Tesamorelin with integrase inhibitors: a subgroup of an earlier trial
A subgroup analysis used an existing blinded trial to examine people with HIV receiving integrase-inhibitor-based treatment.
Read the study note ↗Analytical study
GHK-Cu carriers: encapsulation and enzyme assays answer different questions
Anionic and cationic liposomes were compared for size, bilayer properties, encapsulation and selected enzyme-assay responses.
Read the study note ↗Clinical trial
Mazdutide: a phase 2 study in China
A regional phase 2 study examined a dual GLP-1 and glucagon receptor approach.
Read the study note ↗Clinical trial
MMPOWER-3: a larger trial that did not meet its primary endpoints
Negative primary results are an important part of an evidence library.
Read the study note ↗Clinical trial
OASIS 1: an oral formulation is not interchangeable with other semaglutide materials
The study investigated a specific oral pharmaceutical formulation in adults without diabetes.
Read the study note ↗Analytical study
Proteotypic peptide stability: choosing quantitative surrogates
A proteomics study measured human proteotypic-peptide stability over time and trained a sequence-based prediction model.
Read the study note ↗Clinical trial
Retatrutide in type 2 diabetes: glucose and weight endpoints
This phase 2 study examined glycemic control alongside body weight.
Read the study note ↗Clinical trial
Retatrutide: what the phase 2 obesity trial established
A triple-receptor approach was evaluated in an early controlled obesity study.
Read the study note ↗